The 90-kD lung endothelial cell adhesion molecule-i (Lu-ECAM-1) selectively promotes Ca2"-dependent adhesion of lung-metastatic B16 melanoma cells. Corresponding with their metastatic performance, high lung-metastatic B16-F1O melanoma cells bind in significantly higher numbers to Lu-ECAM-1 than their intermediate and low lung-metastatic counterparts B16-L8-F10 and B16-F0, respectively. Maximum attachment is observed at a density of 2.4 X 102 Lu-ECAM-1 sites/,m2 of plastic surface. B16 melanoma cell binding to Lu-ECAM-1 is blocked by mAb 6D3 and is competitively inhibited by soluble Lu-ECAM-1. C57BI/6 mice passively immunized with anti-Lu-ECAM-1 mAb 6D3 or actively immunized with purified Lu-ECAM-1 exhibit an anti-Lu-ECAM-1 antibody titerdependent reduction in the number of B16 experimental metastases. Lu-ECAM-1 promotes neither binding nor metastasis of other lung-metastatic tumor cells (e.g., KLN205). Our data indicate that an "antiadhesion" therapy directed at interfering with the adherence of blood-borne tumor cells to organ-specific vascular endothelium is efficient in the control of metastasis formation in selective organ sites. (J. Clin. Invest. 1992.
Introduction
Adhesion molecules expressed by vascular endothelial cells have been implicated with the arrest of blood-borne cancer cells in selected secondary organ sites and the initiation of extravasation (1) (2) (3) (4) (5) (6) . These endothelial cell adhesion molecules (ECAMs)' are part of an organ-specific, constitutive vascular phenotype that appears to be regulated through complex interactions with components ofthe extracellular matrix (7, 8) . Similar to the adhesion molecules of high endothelial venules that direct the homing oflymphocytes to selective lymphoid tissues (9) (10) (11) , organ-specific ECAMs serve as attachment sites for blood-borne cancer cells and, thus, determine the tumor-specific metastatic organ colonization patterns known for many years by clinical oncologists (12) (13) (14) . Using a unique large-vessel endothelial cell system in which an organ-specific vascular phenotype can be induced by growing "neutral" bovine aortic endothelial cells (BAEC) on matrix extracts ofthat organ (7) , a lung-specific endothelial cell adhesion molecule (Lu-ECAM-1) has recently been isolated by our laboratory (6, 15) . A monoclonal antibody (mAb 6D3) developed against this molecule, cross-reacts with a murine homologue expressed on the endothelial cell lumenal membrane of selected branches of mouse pulmonary veins. Lu-ECAM-1 selectively promotes the attachment oflung-metastatic B 16 melanoma cells and mediates metastatic colonization of the lungs by these tumor cells (6) .
The critical dependence of blood-borne cancer cells upon organ-specific endothelial cell adhesion molecules in metastasis may provide a unique opportunity of interfering with the metastatic cascade. The concept ofinterfering with cell-cell adhesion phenomena to achieve a therapeutic advantage has recently been introduced to combat excessive leukocyte participation and associated tissue damage in acute and chronic allergic, autoimmune, and inflammatory diseases (16) (17) (18) . Many ofthe published reports have used a mAb directed against CD18 that prevents binding of leukocytes via its LFA1 or Macd receptors to endothelial cells. This mAb has a remarkable ability to prevent various forms of neutrophil-mediated ischemia-reperfusion damages in rabbits when administered at the time of perfusion. Therapeutic blocking ofthe endothelial cell rather than the leukocyte adhesion partner has been demonstrated in a model of bronchial asthma in which airway eosinophilia and hyperresponsiveness are attenuated by daily intravenous treatment of primates with a mAb directed against intercellular adhesion molecule-I (ICAM-1) (18) . These results are intriguing, not only as proof that leukocyte migration is an important factor in these disease states, but as evidence that new therapies can be based on blocking specific adhesion pathways (17) . In this report, we investigate two different strategies ofpreventing B16-F1O melanoma metastasis by interfering with the adhesion of melanoma cells to Lu-ECAM-1. The first strategy relies on the blocking of murine Lu-ECAM-1 by a monospecific mAb (6D3). In the second strategy, mice are actively immunized against bovine Lu-ECAM-1 and, after developing satisfactory antibody titers, are challenged with high lung-metastatic B16-F1O melanoma cells. Both of these "antiadhesion" therapies drastically reduce experimental B 16 metastases.
Methods
Cell culture. Endothelial cells are routinely isolated from thoracic aortas of 18-mo-old bovines, essentially as described by Booyse et al. (19) . BAEC are grown in DME medium supplemented with 10% heat inactivated fetal bovine serum (FBS) . After Modulation ofBAEC with lung matrix extracts. BAEC are modulated to express lung-specific endothelial cell adhesion molecules by growing them on extracellular matrix extracts ofthe lungs (6, 7) . Extracellular matrix is prepared from the lungs of 18-mo-old bovines, as described in detail elsewhere (7, 22) . Lung matrix free of lipids and nucleic acids is extracted overnight at 4VC with 0.5 N acetic acid (10 ml/g of matrix powder Immunoaffinity purification of Lu-ECAM-J. Lu-ECAM-l is isolated and purified by immunoaffinity chromatography from both detergent extracts of lung matrix-modulated BAEC and murine lungs, using anti-Lu-ECAM-I mAb 6D3 as described in detail by our laboratory (6 adhesion medium (1 mM), but is unaffected by Mg2" (Fig. 2) .
The binding affinity ofB 16 cell variants for Lu-ECAM-I correlates well with their propensity of colonizing the lungs (Table  I) (Figs. 1 and 3) . The preferential binding oflung-metastatic B 16 melanoma cells to Lu-ECAM-I is significantly inhibited by anti-Lu-ECAM-1 mAb 6D3 (Fig. 1) . At each coating density of Lu- ECAM-l, mAb 6D3 (10 Ag/ml) reduces binding of the three (Fig. 4) vein-injected B16-FIO melanoma cells in untreated C57B1/6 mice and in mice treated with anti-Lu-ECAM-1 mAb 6D3. Lung clearance is rapid in both animal groups and is accomplished primarily within the first 12 h after intravenous injection of B16-F1O (Table II) (Table III ; Fig. 5 ). The efficiency of inhibition of experimental metastases is dependent upon the anti-Lu-ECAM-l serum titer ofthe immunized mice. At a titer of 1:1,000 an average of 21±6 B16-F10 tumor colonies are counted, but only 9±3 colonies are observed in mice with serum titers of 1:2,000 (P < 0.05) (Table III) (35, 36) and laminin (YIGSR) (37) are able to block tumor cell adhesion to these matrix macromolecules in vitro, and, in accordance, reduce the number ofexperimental metastases in vivo (37) (38) (39) .
In this report, we show that inhibition oftumor cell binding to endothelia of the secondary target organ results in a significant reduction ofexperimental metastases. This inhibition can be achieved by two antiadhesion strategies. The first relies on the inoculation of anti-Lu-ECAM-l mAb 6D3 before challenge ofthe host animal with B 16 melanoma cells. The second is based on an active immunization of tumor-recipient mice with immunoaffinity-purified Lu-ECAM-1. These experiments show that lung metastasis of B16-FI0 melanoma cells critically depends upon the adherence to Lu-ECAM-1, and that other lung-metastatic tumor cells that do not adhere to Lu-ECAM-I in vitro are not affected in their metastatic performance. The importance of Lu-ECAM-l in the formation of lung metastases is further underscored by the clearance rates of intravenous-inoculated B16-F10 melanoma cells from the lungs ofuntreated mice and mice treated with anti-Lu-ECAM-1 mAb 6D3. These rates show that B16-F10 are more rapidly cleared from anti-Lu-ECAM-l mAb 6D3-treated mice than from untreated controls, and that mAb 6D3 is effective during the early phase of metastatic lung colonization, i.e., during the phase that precedes tumor cell extravasation (0-48 h) and which is dominated by tumor cell adhesion to endothelium (40) . Our studies and those previously reported on the inhibition of tumor cell binding to platelets and matrix macromolecules (predominantly basement membrane components) show that the metastatic cascade can be successfully interrupted at various stages, resulting in reduction of metastases (38, 39). The interruption of the metastatic cascade at the endothelial level has the distinct advantage that cancer cells are kept within the circulation where they continue to be subjected to elimination by hemodynamic and geometric forces shown to be most efficient in their eradication (41, 42) .
Our results on the inhibition of metastases by antiadhesion therapies complement recent reports on the successful use of antiadhesion therapies in the combat of excessive leukocyte participation and associated tissue damage in autoimmune, allergic, and inflammatory disorders (16) (17) (18) . Such antiadhesion therapies have been tested in a number of animal models of inflammation using mAbs to various adhesion proteins. Most notably, these antibodies have been directed against CD1 8, and, in some instances, CDl lb and CD54 (16) . The results have been striking and have promoted interest in clinical trials in myocardial infarction, shock, and renal allografts rejection. In cancer, our experiments show that antiadhesion therapies directed at interfering with the adhesion between blood-borne cancer cells and organ-specific vascular endothelia could be exploited in preventing the formation ofsecondary tumor colonies in distant organs. However, the applicability ofsuch therapies is somewhat restrained by the fact that various cancer types appear to recognize and adhere to distinct endothelial cell adhesion molecules (1-8, 43, 44 
